CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Qualigen Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Qualigen Therapeutics Inc
2042 Corte Del Nogal
Phone: (760) 918-9165p:760 918-9165 CARLSBAD, CA  92011  United States Ticker: QLGNQLGN
Business Summary
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Director CampbellBecher 53 9/23/2024 7/5/2024
Interim Chief Executive Officer and Interim Chief Financial Officer, Director KevinRichardson 9/26/2024 9/26/2024
Independent Director GraydonBensler 11/21/2024 11/21/2024
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Qualigen, Inc. 2042 Corte Del Nogal Carlsbad CA United States

Business Names
Business Name
NanoSynex Ltd.
QLGN
Qualigen, Inc.
Qualigen, Inc.
RTTR

General Information
Number of Employees: 4 (As of 3/25/2024)
Outstanding Shares: 736,431 (As of 11/12/2024)
Shareholders: 287
Stock Exchange: NASD
Federal Tax Id: 201295171
Fax Number: (310) 919-1600
Email Address: info@ritterpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024